Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma

Zhang,Xin; Tang,Wei; Li,Ruishan; He,Rongquan; Gan,Tingqing; Luo,Yihuan; Chen,Gang; Rong,Minhua

doi:10.3892/etm.2016.3613

Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma

Authors:
- Xin Zhang
- Wei Tang
- Ruishan Li
- Rongquan He
- Tingqing Gan
- Yihuan Luo
- Gang Chen
- Minhua Rong
View Affiliations

Affiliations: Research Department, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Medical Oncology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Pathology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: August 23, 2016 https://doi.org/10.3892/etm.2016.3613
Pages: 2095-2101
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although miR-132 has been studied in various human tumors, few studies have investigated the role of miR‑132 in hepatocellular carcinoma (HCC). The present study aimed to evaluate the associations between miR-132 and clinicopathological parameters, including recurrence, in patients with HCC. Reverse transcription‑quantitative polymerase chain reaction analysis was used to detect the expression levels of miR‑132 in 95 cases of HCC and their corresponding non‑cancerous liver tissues. Th e associations between miR‑132 expression levels and clinicopathological characteristics, including recurrence, were investigated in patients with HCC. miR‑132 expression levels were significantly reduced in HCC tissues, as compared with adjacent non‑cancerous tissues (1.9245±0.7564 vs. 2.7326±1.1475; P<0.001). The area under curve (AUC) of receiver operating characteristic (ROC) used to distinguish cancerous and non‑cancerous tissues was 0.711 for miR‑132 expression (95% confidence interval, 0.637‑0.785; P<0.001) and the optimal cut‑off value was 2.25. Expression levels of miR‑132 were significantly reduced in the distant metastasis (P=0.031), advanced clinical TNM stage (P=0.022), hepatitis B virus‑positive (P<0.001), NM23‑expressed (P=0.034), high Ki‑67 labeling index (LI; P=0.005) and tumor infiltration or no capsule groups (P=0.026). Spearman correlation analysis demonstrated that miR‑132 was significantly correlated with hepatitis B virus infection (r=‑0.351; P<0.001), NM23 (r=‑0.220; P=0.032), Ki‑67 LI (r=‑0.264; P=0.010) and tumor capsule (r=‑0.207; P=0.044). Kaplan‑Meier analysis with the log‑rank test indicated an approximate difference of 8 months, although miR‑132 may exhibit inferior values for the prediction of recurrence in HCC patients (50.95 vs. 58.68 months; P=0.512). Therefore, the findings of the present study indicated that miR‑132 is downregulated in HCC and may serve as a tumor suppressor in its progression.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Schwartz M, Roayaie S and Konstadoulakis M: Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 4:424–432. 2007. View Article : Google Scholar : PubMed/NCBI
3	El-Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 134:1752–1763. 2008. View Article : Google Scholar : PubMed/NCBI
4	Blum HE: Hepatocellular carcinoma: Therapy and prevention. World J Gastroenterol. 11:7391–7400. 2005.PubMed/NCBI
5	Cho WC: OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
6	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
7	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
9	Li G, Shen Q, Li C, Li D, Chen J and He M: Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: A systematic review and meta-analysis. Clin Transl Oncol. 17:684–693. 2015. View Article : Google Scholar : PubMed/NCBI
10	Zhang K, Zhang Y, Liu C, Xiong Y and Zhang J: MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential (review). Int J Oncol. 45:950–958. 2014.PubMed/NCBI
11	Usó M, Jantus-Lewintre E, Sirera R, Bremnes RM and Camps C: miRNA detection methods and clinical implications in lung cancer. Future Oncol. 10:2279–2292. 2014. View Article : Google Scholar : PubMed/NCBI
12	Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, et al: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI
13	Zheng YB, Luo HP, Shi Q, Hao ZN, Ding Y, Wang QS, Li SB, Xiao GC and Tong SL: miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2. World J Gastroenterol. 20:6515–6522. 2014. View Article : Google Scholar : PubMed/NCBI
14	Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, et al: Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, −224, −132 and let7g. Radiother Oncol. 108:451–457. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhang ZG, Chen WX, Wu YH, Liang HF and Zhang BX: MiR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochem Biophys Res Commun. 454:109–114. 2014. View Article : Google Scholar : PubMed/NCBI
16	Li S, Meng H, Zhou F, Zhai L, Zhang L, Gu F, Fan Y, Lang R, Fu L, Gu L and Qi L: MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract. 209:179–183. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J, Zhou J, Wu J and Shao C: Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 32:1183–1189. 2011. View Article : Google Scholar : PubMed/NCBI
18	Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ and Schmittgen TD: miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 406:518–523. 2011. View Article : Google Scholar : PubMed/NCBI
19	Luo G, Long J, Cui X, Xiao Z, Liu Z, Shi S, Liu L, Liu C, Xu J, Li M and Yu X: Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Int J Oncol. 42:979–984. 2013.PubMed/NCBI
20	Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H, Sherman S and Korc M: A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol. 109:1942–1952. 2014. View Article : Google Scholar : PubMed/NCBI
21	Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agrò E, et al: DNA methylation silences miR-132 in prostate cancer. Oncogene. 32:127–134. 2013. View Article : Google Scholar : PubMed/NCBI
22	Liu X, Yu H, Cai H and Wang Y: The expression and clinical significance of miR-132 in gastric cancer patients. Diagn Pathol. 9:572014. View Article : Google Scholar : PubMed/NCBI
23	Liu Q, Liao F, Wu H, Cai T, Yang L, Wang ZF and Zou R: Upregulation of miR-132 expression in glioma and its clinical significance. Tumour Biol. 35:12299–12304. 2014. View Article : Google Scholar : PubMed/NCBI
24	Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupré I, Rolland D, Salon C, Godfraind C, de Fraipont F, et al: MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One. 6:e206002011. View Article : Google Scholar : PubMed/NCBI
25	Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, Liu R and Wu Z: Epigenetic repression of miR-132 expression by the hepatitis B virus × protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal. 25:1037–1043. 2013. View Article : Google Scholar : PubMed/NCBI
26	Gan TQ, Tang RX, He RQ, Dang YW, Xie Y and Chen G: Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance. Int J Clin Exp Med. 8:714–721. 2015.PubMed/NCBI
27	Pan L, Huang S, He R, Rong M, Dang Y and Chen G: Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res. 19:682014. View Article : Google Scholar : PubMed/NCBI
28	Rong M, He R, Dang Y and Chen G: Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci. 119:19–24. 2014. View Article : Google Scholar : PubMed/NCBI
29	Rong M, Chen G and Dang Y: Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer. 13:212013. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Xu G, Shen F and Kang Y: miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells. Tumour Biol. 35:4859–4865. 2014. View Article : Google Scholar : PubMed/NCBI
32	Renjie W and Haiqian L: MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer Lett. 356:568–578. 2015. View Article : Google Scholar : PubMed/NCBI
33	You J, Li Y, Fang N, Liu B, Zu L, Chang R, Li X and Zhou Q: MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2. PLoS One. 9:e918272014. View Article : Google Scholar : PubMed/NCBI
34	Zhang B, Lu L and Zhang X, Ye W, Wu J, Xi Q and Zhang X: Hsa-miR-132 regulates apoptosis in non-small cell lung cancer independent of acetylcholinesterase. J Mol Neurosci. 53:335–344. 2014. View Article : Google Scholar : PubMed/NCBI
35	Parker NR, Correia N, Crossley B, Buckland ME, Howell VM and Wheeler HR: Correlation of MicroRNA 132 Up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant temozolomide chemotherapy. Transl Oncol. 6:742–748. 2013. View Article : Google Scholar : PubMed/NCBI
36	Yang J, Gao T, Tang J, Cai H, Lin L and Fu S: Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma. Mol Cell Biochem. 381:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
37	Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T and Lee KW: Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. Int J Gynecol Cancer. 23:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
38	Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P and Sarin SK: Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: A case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 22:1104–1111. 2007. View Article : Google Scholar : PubMed/NCBI
39	Takada S and Koike K: Trans-activation function of a 3′truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc Natl Acad Sci USA. 87:5628–5632. 1990. View Article : Google Scholar : PubMed/NCBI
40	Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D and Hadziyannis S: Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat. 12:635–641. 2005. View Article : Google Scholar : PubMed/NCBI